Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERBITUX – cetuximab with concomitant radio-chemotherapy in locally advanced non-small cell lung cancer
2008-005013-21Phase 2Active
- Sponsor
- Institut de Cancérologie Lucien Neuwirth
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of cetuximab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Institut de Cancérologie Lucien Neuwirth. Primary endpoint: Primary feasibility and toxicity endpoint. Started Mar 2009; status: active.
02
Drugs
cetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-005013-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005013-21.